Owen Mumford Announces Verified Science-based Targets & Plans for Net zero

Owen Mumford, a global leader in the design, manufacture and advancement of medical devices, has announced its emissions reduction targets through the Science Based Targets initiative (SBTi). The company has set a target to achieve net zero by 2045 (to mirror the UK NHS target) in alignment with the recommendations of the 2015 Paris Agreement.

Using science-based targets, companies can determine how much and how quickly they need to reduce their greenhouse gas (GHG) emissions to prevent the worst effects of climate change. The Science Based Targets initiative (SBTi) sets science-based emissions reduction targets in line with climate science, supporting companies as they mobilise ambitious climate action efforts in the private sector. Over 2,000 companies worldwide have already set their targets.

As part of its sustainability action plan, the company has joined the Business Ambition for 1.5°c commitment and is one of the first 1000 global businesses to sign up. Launched in 2019, the initiative asks members to pledge to achieve net zero emissions by the latest 2050 following the United Nations Intergovernmental Panel on Climate Change (IPCC) warning that an increase of 1.5°c in global temperature will have catastrophic effects.

By joining the commitment, Owen Mumford also joins the Race to Zero movement, a collaborative effort of leaders across the globe supporting efforts to achieve zero carbon recovery. Owen Mumford recently became one of the first medical device manufacturers in the world to achieve B Corp certification following the establishment of its sustainability programme in 2014 and formal commitment to the United Nation’s Sustainable Development Goals (SDGs). To formalise the pledge to reduce the environmental impact of its operations, Owen Mumford has now set a science-based target, with its base year as 2015. The company will establish a pathway in 2022, including milestones to mark the achievement of goals and measure its success. The focus will be on Scope 3 emissions, which covers factors such as purchased goods and services, business travel and waste disposal.

Jarl Severn, CEO at Owen Mumford
Jarl Severn, CEO at Owen Mumford

Jarl Severn, CEO at Owen Mumford said: “Owen Mumford has been an innovator of medical devices for decades, and we understand the importance of leading by example when it comes to the environment and our impact as a business. Setting a science-based target with the SBTi will hold us accountable and help us to reach our net zero target for 2045. We hope this commitment will inspire other businesses to implement their own sustainability targets and work towards the goal of a carbon neutral future.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version